Roche has gained FDA approval for OCREVUS ZUNOVO™, a treatment for multiple sclerosis using Halozyme's ENHANZE® drug delivery technology. The medication is administered as a subcutaneous injection twice a year by a healthcare professional.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing